Tildrakizumab for treatment of moderate to severe psoriasis: an expert opinion of efficacy, safety, and use in special populations

Figures & data

Figure 1. PASI responses to tildrakizumab 100 mg for up to 244 weeks. Adapted from [18] with permission.

Figure 2. Percentage PASI responses to tildrakizumab 100 mg by week‐28 PASI response groups from a post hoc analysis of reSurface 1 and 2 (575 in the 100-mg and 578 in the 200-mg cohorts). Adapted from [21] with permission.

Table 1. Summary of safety profile of tildrakizumab at 5 years. Adapted from [18] with permission

	Tildrakizumab 100 mg (N = 872)	Tildrakizumab 200 mg (N = 928)
Total follow-up, patient-years	2668.4	2753.5
Severe infection	33 1.2 (0.8–1.7)	37 1.3 (0.9–1.9)
Malignancy excluding NMSC	20 0.7 (0.5–1.1)	17 0.6 (0.4–1.0)
NMSC	12 0.4 (0.2–0.8)	11 0.4 (0.2–0.7)
Melanoma	2 0.1 (0–0.3)	3 0.1 (0–0.3)
Confirmed extended MACE	14 0.5 (0.3–0.9)	20 0.7 (0.4–1.1)
Injection site reaction^a	33 1.2 (0.8–1.7)	41 1.5 (1.1–2.0)
Drug-related hypersensitivity reaction	7 0.3 (0.1–0.5)	4 0.1 (0–0.4)

Data shown as N followed by events per 100 patient-years of exposure (95% CI).

^aNot recorded during the extension studies.

TIL, tildrakizumab; NMSC, non-melanoma skin cancer; MACE, major adverse cardiovascular events; CI, confidence interval.

Figure 3. Efficacy and durability of tildrakizumab by metabolic syndrome status over 148 weeks. Adapted from [39] with permission.

Thaci D, Piaserico S, Warren RB, et al. Five-year efficacy and safety of tildrakizumab in patients with moderate to severe psoriasis who respond at week 28: pooled analyses of two randomised phase 3 clinical trials (reSURFACE 1 and reSURFACE 2). Br J Dermatol. 2021;185(2): 323–334.

 PubMed Web of Science ®Google Scholar

Blauvelt A, Sofen H, Papp K, et al. Tildrakizumab efficacy and impact on quality of life up to 52 weeks in patients with moderate-to-severe psoriasis: a pooled analysis of two randomized controlled trials. J Eur Acad Dermatol Venereol. 2019;33(12):2305–2312.

 PubMed Web of Science ®Google Scholar

Lebwohl MG, Leonardi CL, Mehta NN, et al. Tildrakizumab efficacy, drug survival, and safety are comparable in patients with psoriasis with and without metabolic syndrome: long-term results from 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2). J Am Acad Dermatol. 2021;84(2):398–407.

 PubMed Web of Science ®Google Scholar